竞争风险模型与血管生成因子在孕中期筛查早产生长相关新生儿疾病中的比较
这项前瞻性观察研究纳入两家英国产科医院19-24周常规产检的40241名孕妇,比较低PlGF、高sFlt-1/PlGF比值与SGA竞争风险模型对早产生长相关新生儿疾病的预测效能。在10.0%筛查阳性率下,竞争风险模型对<32周分娩且新生儿病房住院≥48小时的SGA<10百分位和<3百分位的检出率分别为70.1%和76.9%,显著高于sFlt-1/PlGF比值>90百分位的35.1%和35.9%(均P<0.0001)。
要点
- 孕中期SGA竞争风险模型对早产生长相关新生儿疾病的预测优于低PlGF或高sFlt-1/PlGF比值。
- 在10.0%筛查阳性率下,竞争风险模型对<32周分娩SGA<10百分位合并新生儿病房住院≥48小时的检出率为70.1%。
- 低PlGF与高sFlt-1/PlGF比值筛查的检出率均显著低于竞争风险模型(均P<0.0001)。
核心结论
- 孕中期SGA竞争风险模型对生长相关新生儿疾病的预测优于高sFlt-1/PlGF比值或低PlGF。
研究设计与样本
- 前瞻性观察研究,纳入两家英国产科医院19-24周常规产检孕妇40241名。
- 筛查方法包括孕妇人口学特征与病史、超声估计胎儿体重及子宫动脉搏动指数,并检测血清PlGF和sFlt-1。
- 主要结局为<32周和<37周分娩SGA新生儿(出生体重<10百分位或<3百分位)合并新生儿病房住院≥48小时或主要新生儿疾病复合终点。
诊断标准与关键数值
- 以sFlt-1/PlGF比值>90百分位定义10.0%筛查阳性率时,竞争风险模型对<32周分娩SGA<10百分位合并新生儿病房住院≥48小时的检出率为70.1%(95%CI 61.0-79.2%)。
- 同一条件下,竞争风险模型对<32周分娩SGA<3百分位合并新生儿病房住院≥48小时的检出率为76.9%(95%CI 67.6-86.3%)。
- 同一条件下,竞争风险模型对<32周分娩SGA<10百分位合并主要新生儿疾病的检出率为73.8%(95%CI 64.4-83.2%)。
- 同一条件下,竞争风险模型对<32周分娩SGA<3百分位合并主要新生儿疾病的检出率为77.9%(95%CI 68.0-87.8%)。
- sFlt-1/PlGF比值>90百分位对应的上述四项检出率分别为35.1%(95%CI 25.6-44.6%)、35.9%(95%CI 25.3-46.5%)、38.1%(95%CI 27.7-48.5%)和39.7%(95%CI 28.1-51.3%),均显著低于竞争风险模型(均P<0.0001)。
临床应用与阅片要点
- 孕中期筛查可考虑采用SGA竞争风险模型整合母体风险因素、超声估计胎儿体重和子宫动脉搏动指数预测早产生长相关新生儿疾病。
- 低PlGF或高sFlt-1/PlGF比值单指标筛查的检出率显著低于竞争风险模型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: First, to evaluate the predictive performance for preterm growth-related neonatal morbidity of a high soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio or low PlGF at midgestation and, second, to compare the performance of a high sFlt-1/PlGF ratio or low PlGF with that of the competing-risks model for small-for-gestational age (SGA), utilizing a combination of maternal risk factors, sonographic estimated fetal weight and uterine artery pulsatility index.
METHODS: This was a prospective observational study in women attending for a routine hospital visit at 19-24 weeks' gestation in two maternity hospitals in England. The visit included recording of maternal demographic characteristics and medical history, carrying out an ultrasound scan and measuring serum PlGF and sFlt-1. The primary outcome was delivery < 32 and < 37 weeks' gestation of a SGA neonate with birth weight < 10th or < 3rd percentile, combined with neonatal unit (NNU) admission for ≥ 48 h or a composite of major neonatal morbidity. The detection rates in screening by PlGF < 10th percentile, sFlt-1/PlGF ratio > 90th percentile and the competing-risks model for SGA were estimated and then compared using McNemar's test.
RESULTS: In the study population of 40 241 women, prediction of preterm growth-related neonatal morbidity provided by the competing-risks model for SGA was superior to that of screening by low PlGF concentration or high sFlt-1/PlGF ratio. For example, at a screen-positive rate of 10.0%, as defined by the sFlt-1/PlGF ratio > 90th percentile, the competing-risks model predicted 70.1% (95% CI, 61.0-79.2%) of SGA < 10th percentile and 76.9% (95% CI, 67.6-86.3%) of SGA < 3rd percentile with NNU admission for ≥ 48 h delivered < 32 weeks' gestation. The respective values for SGA with major neonatal morbidity were 73.8% (95% CI, 64.4-83.2%) and 77.9% (95% CI, 68.0-87.8%). These were significantly higher than the respective values of 35.1% (95% CI, 25.6-44.6%), 35.9% (95% CI, 25.3-46.5%), 38.1% (95% CI, 27.7-48.5%) and 39.7% (95% CI, 28.1-51.3%) achieved by the application of the sFlt-1/PlGF ratio > 90th percentile (all P < 0.0001).
CONCLUSION: At midgestation, the prediction of growth-related neonatal morbidity by the competing-risks model for SGA is superior to that of a high sFlt-1/PlGF ratio or low PlGF. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Papastefanou I, Menenez M, Szczepkowska A, et al. Comparison of competing-risks model with angiogenic factors in midgestation screening for preterm growth-related neonatal morbidity. Ultrasound Obstet Gynecol. 2024. PMID: 38057964. doi:10.1002/uog.27559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。